Ajanta Pharma on Monday said its consolidated profit after tax increased 4% year-on-year to ₹255 crore in the first quarter ended June 30, 2025, aided by robust sales of branded generics.
The Mumbai-based drug maker reported a profit after tax (PAT) of ₹246 crore in the June quarter of the last fiscal.
Revenue from operations rose to ₹1,303 crore in the period under review as compared with ₹1,145 crore in the year-ago period, Ajanta Pharma said in a regulatory filing.
The company's sales of branded generics in India, Asia and Africa climbed by 9% year-on-year to ₹941 crore in the April-June quarter this fiscal.
Sales of generics in the US market stood at ₹310 crore in the June quarter, a growth of 36 per cent year-on-year, as against ₹228 crore in the same period last year.
Shares of the company ended 0.99% down at ₹2,753.65 apiece on the BSE.
